Abstract 1365P
Background
Lorlatinib (LOR), a 3rd generation tyrosine kinase inhibitor (TKI), has shown promising activity in NSCLC. However, the treatment has been associated with an increasing number of neurocognitive adverse events (NAEs). This systematic review and meta-analysis evaluated the NAEs associated with LOR therapy in NSCLC patients.
Methods
PubMed, Scopus, and the Cochrane Library were searched for clinical trials and observational cohort studies investigating LOR for NSCLC patients. NAEs were defined as the cluster terms of cognitive effects, mood effects, speech effects, and psychotic effects. Heterogeneity was examined with the I2 statistics and random-effect model was used to pool studies.
Results
Sixteen studies were included with 1,147 patients, of whom 56% were female, 8% were Asians, 8% had a history of smoking, 62% had brain metastasis, and 1% ECOG 2 or higher. Most patients had previously received an early-generation TKI before the LOR. A pooled analysis of NAEs showed a prevalence of cognitive effects in 15.57% of overall population (95% CI 8.40 – 22.73, I2 90%), mood effects in 11.93% (95% CI 5.80 – 18.06, I2 89%), speech effects in 6.56% (95% CI 1.79 – 11.34, I2 91%), and psychotic effects in 4.15% (95% CI 1.46 – 6.83, I2 74%). In a subgroup analysis, we found higher rates of cognitive effects in clinical trials than in real-world data (23.57% vs. 9.36%, p = 0.05), and a significant difference was also seen in mood effects (18.64% vs. 3.70%, p < 0.01). NAEs were manageable with dose modification, temporary interruption, and/or concomitant medication.
Conclusions
Our study revealed that LOR is associated with cognitive, mood, speech and psychotic effects in approximately 16%, 12%, 7%, and 4% of patients, respectively. We found significant differences in the prevalence of cognitive and mood effects between clinical trials and real-world data. Additionally, all analyses had a high heterogeneity among studies. Collectively, these findings underscore the importance of educating patients and healthcare professionals regarding LOR-associated NAEs to facilitate early detection and management of NAEs, aiming to improve NSCLC patients' quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19
1058P - Intraperitoneal nivolumab for malignant ascites in patients with advanced gastrointestinal or pancreaticobiliary tract cancer
Presenter: Hsiu-Tzu Wang
Session: Poster session 19
1059P - Tertiary lymphoid structures localization and maturation heterogeneities correlate with divergent clinical outcomes and immune responses of clear cell renal cell carcinoma
Presenter: Dingwei Ye
Session: Poster session 19
1061P - Association of transcriptomic mapping of tumors with high expression of Tregs to identify surfaceome gene signatures with efficacy to check point inhibitors
Presenter: María Del Mar Noblejas Lopez
Session: Poster session 19
1062P - Anti-PD1 efficacy in European patients with advanced MSI-H/MMRd non-colorectal cancers
Presenter: Christophe Tournigand
Session: Poster session 19
1063P - Differential tumor responses are a poor prognostic factor in patients receiving immune checkpoint inhibitors
Presenter: Caterina Tozzi
Session: Poster session 19
1065P - Prospective assessment of nutritional status in patients with advanced non-small cell lung cancer and renal cell carcinoma treated with immune checkpoint inhibitors
Presenter: Federica Pecci
Session: Poster session 19
1066P - Negative impact of steroids on the efficacy of immunotherapy in a multi-tumor cohort of patients: time and dose-dependent
Presenter: Víctor Albarrán
Session: Poster session 19
1067P - The interchangeability of Immune checkpoint inhibitors
Presenter: Lonneke Timmers
Session: Poster session 19